Unbalanced Inhibitory/Excitatory Responses in the Substantia Nigra Pars Reticulata Underlie Cannabinoid-Related Slowness of Movements

• Published in: The Journal of neuroscience Vol. 40; no. 30; pp. 5769 - 5784
• Main Authors: Báez-Cordero, Ana S, Pimentel-Farfan, Ana K, Peña-Rangel, Teresa, Rueda-Orozco, Pavel E
• Format: Journal Article
• Language: English
• Published: United States Society for Neuroscience 22.07.2020
• Subjects: Animals; Basal ganglia; Cannabinoid CB1 receptors; Cannabinoids; Cannabinoids - pharmacology; Carrier Proteins - agonists; Carrier Proteins - antagonists & inhibitors; Carrier Proteins - physiology; Cyclohexanols - pharmacology; Firing pattern; Ganglia; Loci; Male; Movement - drug effects; Movement - physiology; Pars Reticulata; Piperidines - pharmacology; Psychomotor Performance - drug effects; Psychomotor Performance - physiology; Pyrazoles - pharmacology; Rats; Rats, Long-Evans; Substantia nigra; Substantia Nigra - drug effects; Substantia Nigra - physiology; Substantia nigra pars reticulata; Unbalance; cannabinoids; substantia nigra
• ISSN: 0270-6474; 1529-2401
• DOI: 10.1523/JNEUROSCI.0045-20.2020

The substantia nigra pars reticulata (SNr), where the basal ganglia (BG) direct and indirect pathways converge, contains among the highest expression of cannabinoid receptor type 1 (CB1r) in the brain. Hence, SNr is an ideal locus to study pathway interactions and cannabinergic modulations. The objective of this study was to characterize the effects of systemic injections of the CB1r agonist (CP55940) on the balanced activity of the direct/indirect pathways in the SNr and its associated behaviors. To this aim, we recorded somatosensory and pathway-specific representations in the spiking activity of the SNr of male rats under CP55940. CB1r activation mainly decreased the inhibitory, potentially direct pathway component while sparing the excitatory, potentially indirect pathway component of somatosensory responses. As a result, cutaneous stimulation produced unbalanced responses favoring increased SNr firing rates, suggesting a potential locus for cannabinergic motor-related effects. To test this hypothesis, we implemented an behavioral protocol for rats in which systemic administration of CP55940 produced kinematic impairments that were completely reverted by nigral injections of the CB1r antagonist (AM251). Our data suggest that cannabinoid-related motor effects are associated with unbalanced direct/indirect pathway activations that may be reverted by CB1r manipulation at the SNr. The cannabinergic system has been the target of multiple studies to master its potential use as a therapeutic agent. However, significant advances have been precluded by the lack of mechanistic explanations for the variety of its desirable/undesirable effects. Here, we have combined electrophysiological recordings, pharmacological and optogenetic manipulations, and an behavioral protocol to understand how basal ganglia (BG) is affected by cannabinoids. We found that cannabinoids principally affect inhibitory inputs, potentially from the direct pathway, resulting in unbalanced responses in the substantia nigra pars reticulata (SNr) and suggesting a mechanism for the cannabinoid-related slowness of movements. This possibility was confirmed by behavioral experiments in which cannabinoid-related slowness of purposeful movements was reverted by cannabinoid receptor type 1 (CB1r) manipulations directly into the SNr.